Inovio Pharmaceuticals (INO) - חוב לטווח ארוך להון

Inovio Pharmaceuticals (INO) operates in an environment of fierce competition for intellectual property and government support, where success is determined by the pace of drug certification. The visualization of the debt-to-equity ratio is 1.20. Inovio Pharmaceuticals (INO) integrates sustainable development principles into the production of DNA vaccines while adhering to corporate governance ethics. Meanwhile, the business relies on regulatory approvals and sufficient reserves to fund scientific research.

Inovio Pharmaceuticals (INO) focuses on the commercialization of rare lung disease therapies, which requires significant R&D capital expenditures. This long-term debt-to-equity ratio correlates liabilities with maturities exceeding one year to the current market value of equity, allowing for an assessment of the financial stability of the business reboot strategy and the risk of over-leverage when analyzing this chart.